Arcturus Therapeutics Holdings Inc.

NASDAQ•ARCT

CEO: Mr. Joseph E. Payne M.Sc.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2013-05-22

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Contact Information

10628 Science Center Drive, Suite 250, San Diego, CA, 92121, United States

858-900-2660

arcturusrx.com

Market Cap

$191.00M

P/E (TTM)

-2.8

17.2

Dividend Yield

52W High

$24.17

52W Low

$5.85

52W Range

Rank62Top 92.6%

1.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$3.08M+0.00%

4-Quarter Trend

EPS

-$1.05+0.00%

4-Quarter Trend

FCF

-$16.36M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

KOSTAIVE Commercial Sales Begin First sa-mRNA vaccine sales started in Japan Q4 2024; EU/UK approvals secured validation of platform technology.

R&D Spending Significantly Reduced Total R&D expenses fell 43% to $112.2M in 2025, driven by LUNAR-COVID program transition to commercial phase.

Net Loss Narrowed Substantially Net loss improved to ($65.8M) in 2025 from ($80.9M) in 2024, reflecting lower operating expenses across R&D.

Rare Disease Pipeline Advances ARCT-032 (CF) Phase 2 dosing completed; ARCT-810 (OTC) Phase 2 dosing nearing completion with positive interim data.

Risk Factors

Collaboration Revenue Volatility High Total revenue dropped 46% to $82.0M in 2025, heavily reliant on non-recurring milestone payments from CSL Seqirus.

CSL Partnership Financial Strain CSL reported $430M write-down on collaboration citing market decline; potential separation poses further disruption risk.

Future Capital Requirements Expected Expect continued losses; substantial additional capital needed to fund ongoing development and commercialization efforts.

Intellectual Property Litigation Risk Lawsuit filed against AbbVie for trade secret misappropriation; litigation is costly and management attention diversion risk.

Outlook

OTC Pediatric Study Planned Type C meeting with FDA scheduled H1 2026 to discuss ARCT-810 future pediatric study under RDEP guidelines.

CF Efficacy Study Initiation Plan to initiate 12-week safety and preliminary efficacy study for ARCT-032 in CF participants in H1 2026.

Platform Technology Expansion Continue exploratory development evaluating genome editing and new targeting approaches for LUNAR and STARR platforms.

Managing High Operating Costs Expect expenses to increase substantially as R&D advances candidates toward and through necessary clinical trials.

Peer Comparison

Revenue (TTM)

VNDA

$216.11M

+8.7%

RGNX

$170.44M

+104.5%

ARCT

$74.12M

-46.4%

Gross Margin (Latest Quarter)

ABSI

100.0%

+197.2pp

GOSS

98.4%

+0.0pp

VNDA

93.3%

+0.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CRVS	$1.18B	-72.8	-23.3%	1.3%
SVRA	$1.05B	-9.7	-84.0%	11.8%
KALV	$830.48M	-4.2	-282.0%	44.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-52.8%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026

EPS:-$1.01

Revenue:$7.23M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data